Navigation Links
Exemestane plus everolimus increased progression-free survival
Date:12/7/2011

SAN ANTONIO Everolimus in combination with exemestane has shown promise for the treatment of breast cancer.

"For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D., FACP, professor of medicine, chair of the department of breast medical oncology and director of the Multidisciplinary Breast Cancer Research Program at the University of Texas MD Anderson Cancer Center in Houston.

Hortobagyi presented findings from Breast Cancer Trials of Oral Everolimus (BOLERO-2), a phase 3 clinical trial, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

BOLERO-2 researchers enrolled 724 postmenopausal patients with HR-positive metastatic breast cancer and evidence of progressive disease while receiving anastrozole or letrozole. They randomly assigned patients to treatment with exemestane plus everolimus or with exemestane plus placebo.

Results revealed a median progression-free interval of 3.2 months for 239 patients treated with exemestane plus placebo. Among the 485 patients treated with exemestane plus everolimus, researchers found a median progression-free interval of 7.4 months, "a highly significant difference," Hortobagyi said.

Clinical benefit rates, which include complete response, partial response, or stable disease exceeding six months, were 25.5 percent among patients treated with exemestane and placebo and 50.5 percent among those treated with exemestane and everolimus.

"The original hypothesis predicted this increased benefit from the combination, based on compelling preclinical experiments and preliminary results from earlier, smaller clinical trials. These results establish a new standard of care for this group of patients," Hortobagyi said.

He continued, "These results highlight the progress being made in un
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
210-582-7021
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
2. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
3. Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
4. Everolimus improves progression-free survival for patients with rare pancreatic cancer
5. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
6. An important reduction in risk of stent thrombosis with everolimus-eluting stent
7. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
8. Migraine Linked to Increased Heart Attack Risk
9. Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research
10. Increased HAART coverage associated with 50 percent drop
11. RetireSafe Survey Says Seniors Are Struggling With Increased Costs Without an Increased Social Security Cost of Living Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a ... app invention that can help people during emergencies. , "The worldwide mobile health ... Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile health ...
(Date:7/30/2015)... ... 2015 , ... In an effort to provide the twenty four hour continuous ... in his practice. , The decision will also allow him to spend more time ... transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual intended ... Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with the ... most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with the ...
(Date:7/30/2015)... ... 30, 2015 , ... Google recently announced that it will be disclosing any ... in a June 8, 2015 article published by Nasdaq , the powerful tech ... by its computer-driven cars, which such industry players as Tesla CEO Elon Musk believe ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a ... San Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded ... health care providers. 24/7 Care At Home’s agency is one of three top Orange ...
Breaking Medicine News(10 mins):Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2
... women need screening as much as younger ones, , , ... should continue for women older than 50 -- even ... they have a similar level of risk as younger ... there,s little benefit in repeating smear tests in women ...
... As federal policymakers pursue healthcare reform this year, the ... prevention will be critically evaluated. As part of ... North America,s top medical schools will host scientists from ... the area of integrative medicine. The Consortium ...
... genetic study conducted through Mayo Clinic has identified ... European ancestry, according to a recent issue of ... , Research findings indicate that alcohol dependence ... variations associated with this illness remain unknown. Animal ...
... Holistic Addiction Treatment has added the use of Mild Hyperbarics to drug ... Scotland and Russia, mild hyperbarics is not generally associated with drug and ... alcohol treatment and recovery services that meet the needs of the person ... ...
... finds vets at higher risk of aggressive recurrence only ... News) -- U.S. male military veterans exposed to the ... recurrence of prostate cancer, a new study finds. , ... cancerous prostates. Of those, the 206 men who,d been ...
... Health Ministry Official shows programs funded by the Global Fund and President,s ... , ... Washington, DC (PRWEB) April 23, 2009 -- At a Congressional ... discussed the current state of malaria in Rwanda and how ...
Cached Medicine News:Health News:Don't Lower Age for Cervical Cancer Test, Study Urges 2Health News:Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers 2Health News:Mayo clinic study finds gene bringing together animal and human research in alcoholism 2Health News:G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab 2Health News:G & G Holistic Addiction Treatment Uses Innovative Use of Oxygen Therapy Which Restores Mind and Body in Drug Rehab 3Health News:Agent Orange Exposure Tied to Prostate Cancer Return 2Health News:A View from Rwanda: Congressional Briefing Highlights Impact of U.S. funded Anti-Malaria Programs 2Health News:A View from Rwanda: Congressional Briefing Highlights Impact of U.S. funded Anti-Malaria Programs 3
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015 What ... ? Which areas are going to grow at the ... you potential revenues to 2025, assessing data, trends, opportunities ... provides 176 tables, charts, and graphs. Discover the ... market prospects. Our new study lets you assess forecasted ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today announced ... private company that holds certain rights and know-how to poloxamer-based ... the target company. About the ... target company contemplate an all-stock acquisition by merger. Other than ...
... 2011 Amarin Corporation plc (Nasdaq: AMRN ... focus on cardiovascular disease, today announced that, in connection ... Depositary Shares ("ADSs"), the underwriters of the offering have ... an aggregate of 1,800,000 additional ADSs to cover over-allotments. ...
Cached Medicine Technology:ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics 2ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics 3ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics 4ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics 5Amarin Announces Underwriters' Exercise of Over-Allotment Option 2Amarin Announces Underwriters' Exercise of Over-Allotment Option 3Amarin Announces Underwriters' Exercise of Over-Allotment Option 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: